Hoffnung stirbt zum Schluss...!

ist eh null.

ausgebucht oder nicht.  


und neo droht dir das gleiche.  

http://www.cancer.gov/drugdictionary?cdrid=346914
DJ-927  
A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic properties. Oral taxane derivative DJ-927 binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. As the first oral taxane derivative, oral taxane derivative DJ-927 is more potent than paclitaxel and docetaxel. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:  oral taxane derivative DJ-927  

Code name:  DJ927
 

Adenocarcinoma   2 studies
Breast Diseases   2 studies
Breast Neoplasms   2 studies
Carcinoma   5 studies
Carcinoma, Transitional Cell   1 study
Colonic Diseases   1 study
Colonic Neoplasms   1 study
Colorectal Neoplasms   1 study
Digestive System Diseases   4 studies
Digestive System Neoplasms   4 studies
Gastrointestinal Diseases   4 studies
Gastrointestinal Neoplasms   4 studies
Genital Diseases, Male   1 study
Genital Neoplasms, Male   1 study
Intestinal Diseases   1 study
Intestinal Neoplasms   1 study
Lymphoma   1 study
Melanoma   2 studies
Neoplasms, Germ Cell and Embryonal   2 studies
Neoplasms, Glandular and Epithelial   5 studies
Neoplasms, Nerve Tissue   2 studies
Neuroectodermal Tumors   2 studies
Neuroendocrine Tumors   2 studies
Neuroepithelioma   2 studies
Nevus   2 studies
Nevus, Pigmented   2 studies
Prostatic Diseases   1 study
Prostatic Neoplasms   1 study
Rectal Diseases   1 study
Skin Diseases   2 studies
Stomach Carcinoma   3 studies
Stomach Diseases   3 studies
Stomach Neoplasms   3 studies
Transitional Cell Carcinoma   1 study
Urinary Bladder Diseases   1 study
Urinary Bladder Neoplasms   1 study
Urogenital Neoplasms   2 studies
Urologic Diseases   1 study
Urologic Neoplasms   1 study
http://www.clinicaltrials.gov/ct2/results/...amp;brwse=cond_alpha_all  

DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.

Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A.


Author information




Abstract


DJ-927 is a novel taxane, which was selected for high solubility, non-neurotoxicity, oral bioavailability, and potent antitumor activity. In this study, we compared the in vitro and in vivo efficacy of DJ-927 with those of paclitaxel and docetaxel. DJ-927 exhibited stronger cytotoxicity than paclitaxel and docetaxel in various tumor cell lines, especially against P-glycoprotein (P-gp)-expressing cells. The cytotoxicity of DJ-927, unlike those of other taxanes, was not affected by the P-gp expression level in tumor cells, or by the co-presence of a P-gp modulator. When intracellular accumulation of the three compounds was compared, intracellular amounts of DJ-927 were much higher than those of paclitaxel or docetaxel, particularly in P-gp-positive cells. In vivo, DJ-927 showed potent antitumor effects against two human solid tumors in male BALB/c-nu/nu mice, and yielded significant life-prolongation in a murine liver metastasis model with male C57BL/6 mice, in which neither paclitaxel nor docetaxel was effective. The results demonstrate the superior efficacy of orally administered DJ-927 over intravenously administered paclitaxel or docetaxel against P-gp-expressing tumors, probably due to higher intracellular accumulation. A phase I clinical trials of DJ-927 is currently ongoing in the US.
 

http://www.ncbi.nlm.nih.gov/pubmed/12824894  

prolongation in a murine liver metastasis model with male C57BL/6 mice, in which neither paclitaxel nor docetaxel was effective  

olle kamellen  

Acquired Immunodeficiency Syndrome   1 study
Adenocarcinoma   4 studies
Adenoma   1 study
Adenoma, Islet Cell   1 study
Adenoviridae Infections   1 study
Angiomatosis   1 study
Apudoma   2 studies
Arterial Occlusive Diseases   2 studies
Arteriosclerosis   2 studies
Arthritis   1 study
Arthritis, Rheumatoid   1 study
Atherosclerosis   2 studies
Autoimmune Diseases   1 study
B-cell Lymphomas   1 study
Bacterial Infections   1 study
Blood Coagulation Disorders   1 study
Blood Protein Disorders   1 study
Body Temperature Changes   1 study
Body Weight   1 study
Brain Diseases   3 studies
Brain Neoplasms   2 studies
Brain Tumor, Childhood   1 study
Breast Diseases   1 study
Breast Neoplasms   1 study
Carcinoid Tumor   3 studies
Carcinoma   7 studies
Carcinoma, Islet Cell   1 study
Carcinoma, Neuroendocrine   3 studies
Carcinoma, Squamous Cell   1 study
Carotid Artery Diseases   1 study
Cataract   1 study
Central Nervous System Diseases   3 studies
Central Nervous System Neoplasms   2 studies
Cerebrovascular Disorders   1 study
Chorioretinitis   1 study
Choroid Diseases   1 study
Choroiditis   1 study
Connective Tissue Diseases   1 study
Coronary Artery Disease   1 study
Coronary Disease   1 study
Cranial Nerve Diseases   1 study
Craniomandibular Disorders   1 study
Cystic Fibrosis   1 study
Digestive System Diseases   7 studies
Digestive System Neoplasms   5 studies
Endocrine Gland Neoplasms   6 studies
Endocrine System Diseases   6 studies
Eye Diseases   1 study
Facial Nerve Diseases   1 study
Facial Neuralgia   1 study
http://www.clinicaltrials.gov/ct2/...=%22Digestive+System+Diseases%22  

G4544 is an oral tablet formulation of gallium nitrate manufactured using a proprietary drug-delivery technology developed by Emisphere Technologies. The drug is presently in Phase I clinical trials [20]. Preclinical studies in dogs showed that the drug was rapidly absorbed and achieved a mean plasma level of 1800 ng/ml, which was fourfold greater than that achieved with gallium nitrate. Long elimination half-lives of 101 and 338 h were seen in rat and dog, respectively. In a Phase I clinical trial, 30 normal volunteers received a single oral dose of G4544 at doses ranging from 30–150 mg [20]. At the highest dose level, a peak gallium plasma concentration of 485 ng/ml was achieved, which is similar to levels seen with continuous intravenous gallium nitrate. G4544 was tolerated without adverse side effects. These initial Phase I results are encouraging and further trials to examine the efficacy of this agent in skeletal diseases and cancer are planned [20].  

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574811/  

und was soll das heißen ? Ist zu viel !!!  

-> Gallensaft  

tatsächlich eine Menge Treffer. Man darf nicht vergessen, das Genta alle Rechte an Tesetaxel hielt, und sogar einen neuartigen Syntheseweg dazu entwickelt hat.  

einem anderen Arikel:

http://www.ncbi.nlm.nih.gov/pubmed/22900955  

Aber wer hier noch Hoffnung hat soll halt einfach nur warten bis Geld
auf den Konto ist. Mehr kann man nicht mehr tun.
Wer aber es gerne heiß mag der kann auch bei NeoMedia AG einsteigen.
Das ist für mich die heißeste Aktie die ich je hatte.  

Eine Firma, die zwar vielversprechende Rechte an aktiven Pharmazeutika hält, aber von der man schon lange keine Update mehr gehört hat. Neomedia wird wenigstens noch gehandelt.  

aber alles noch in Studien Phase II. Bis es zur Marktreife kommen müste vergehen noch Jahre.
Bis dahin ist Genta längst abgewickelt.
Hat keinen Sinn mehr. Musste es schmerzhaft eingestehen.
 

es gibt eine vorläufige Zulassung. Die Zulassung an sich ist nicht daran gebunden, welche Firma das Recht an der Substanz innehält, sondern ob Tesetaxel die notwendige Wirksamkeit aufweist. Man kann ja immerhin feststellen, das Studien damit noch laufen.  

Wenn eine andere Firma Tesetaxel vermarktet. Also was.soll man sekne
Zeit hier noch verplembern. Kopf hoch und eingestehen was nicht mehr
zu ändern ist. Es gibt noch andere Aktien.  

 

Weiß einer was aktuell ?

Oder sind die schon definitiv  tot?  

Aber nach Fakten Lage ist noch nichts entschieden wie es weiter geht.  

Interessant:

London - Im Jahr 2012 erkrankten 14 Millionen Menschen weltweit neu an Krebs, die Zahl der Betroffenen soll in den nächsten Jahren noch drastisch steigen. Dies ist das Ergebnis des aktuellen Welt-Krebsberichts 2014 der Weltgesundheitsorganisation WHO. Vor allem in Entwicklungsländern könnte demnach der Zugang zu bezahlbaren und effektiven Behandlungsmöglichkeiten vielen Krebskranken das Leben retten.

Quelle:
http://www.spiegel.de/gesundheit/diagnose/...vermeidbar-a-950813.html  

bloß was bringt das hier noch?